一、受体酪氨酸蛋白激酶 受体(Receptor)、酪氨酸(Tyrosine)、蛋白激酶(Kinase)是三个独立的词,但连在一起,“受体”、“酪氨酸”成了“蛋白激酶”的定语,表达出新的意思,它从概念上层层递进,将EGFR进行了归类。 蛋白激酶(Protein Kinase)是一类能够将磷酸基团从供体分子(如ATP)转移到蛋白质底物特定氨基酸残基上的...
Lihong Wei, et al., Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Medi-ating the Response to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer, Clinical Lung Cancer (2025). 往期推荐 参加临床试...
那么TKI是什么呢，Tyrosine kinase inhabitor （酪氨酸激酶抑制剂）。EGFR的靶向药就是这样一种抑制剂。我说了这么多，还是不通俗。举个例子吧，唐玄宗时期，受中央政府（EGFR配体）节制，安禄山与史思明（假设与安一样是节度史），本来是应该齐心合力御外敌安内民的，结果野心膨胀（EGFR基因突变），发动了安史之乱...
10 Li Zhang, Wenfeng Fang, Yuanyuan Zhao, et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMON...
2. Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M. & Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Ann. Oncol.29, i10–i19 (2018). 3. Nahar, R. et al. Elucidating the genomic architecture of Asian EGFR...
EGFR Protein Tyrosine Kinase Substrate 是EGFR 酪氨酸激酶的底物。EGFR（Epidermal Growth Factor Receptor，表皮生长因子受体）Protein Tyrosine Kinase Substrate，即EGFR酪氨酸激酶的底物，是细胞内信号转导途径中的关键分子之一，它在调节细胞生长、增殖、分化以及存活等方面发挥着至关重要的作用。EGFR作为一种跨膜受体...
在非小细胞肺癌(non-small cell lung cancer,NSCLC)的发生发展中,EGFR 可是个 “关键人物”,临床上常用 EGFR 酪氨酸激酶抑制剂(EGFR tyrosine kinase inhibitors,TKIs)来对付它。但时间一长,肿瘤细胞就会 “耍赖皮”,对这些抑制剂产生耐药性,让治疗陷入困境。
[7] Zhang L, et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. 2024 ASCO 8508. ...
5.Zhou Z, Zhao Y, Shen S, Gu L, Niu X, Xu Y, Zhang T, Xiang J, Mao X, Lu S. Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2019 Aug...
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities[J]. Molecular Cancer 2018, 17 (1), 60-72. [17] SIEGELIN M D,BORCZUK A C. Epidermal growth factor receptor mutations in lung adenocarcinoma[J].Lab Invest...